Fatty Acid Synthase: An Emerging Target in Cancer.

Fhu CW, Ali A. · 2020

Read Fatty Acid Synthase: An Emerging Target in Cancer. by Fhu CW, Ali A. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7504791.txt.

Introduction

Fhu and Ali review fatty acid synthase as a rising target in cancer care. Lipid making has drawn fresh focus in tumor research. Tumors need fat building blocks to grow and can burn fat for energy.

The enzyme, called FASN, sits at the center of lipid control. It helps tumors with fat-making traits grow and survive. It can rewire tumor cells for flexible energy use under stress. It also shapes organelle work, sugar use, and amino acid handling. New blockers of FASN are in early clinical trials now. The review gathers proof that this enzyme matters across many cancers. It makes the case for FASN as a drug target worth the trials under way.

Catalog record

CREATORFhu CW, Ali A.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE86 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7504791

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Fatty Acid Synthase: An Emerging Target in Cancer By Chee Wai Fhu, Azhar Ali, Pierluigi Plastina Published in: Molecules DOI: 10.3390/molecules25173935 ABSTRACT Abstract In recent years, lipid metabolism has garnered significant attention as it provides the necessary building blocks required to sustain tumor growth and serves as an alternative fuel source for ATP generation. Fatty acid synthase (FASN) functions as a central regulator of lipid metabolism and plays a critical role in the growth and survival of tumors with lipogenic phenotypes. Accumulating evidence has shown that it is capable of rewiring tumor cells for greater energy flexibility to attain their high energy requirements. This multi-enzyme protein is capable of modulating the function of subcellular organelles for optimal function under different conditions. Apart from lipid metabolism, FASN has functional roles in other cellular processes such as glycolysis and amino acid metabolism. These pivotal roles of FASN in lipid metabolism make it an attractive target in the clinic with several new inhibitors currently being tested in early clinical trials. This article aims to present the current evidence on the emergence of FASN as a target in human malignancies. Keywords: fatty acid synthase, cancer, lipid metabolism 1. INTRODUCTION Cancer hallmarks were introduced by Hanahan et al. in 2010 and these hallmarks encompass six basic tumor characteristics—which are self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue invasion and metastasis, unlimited replication potential, sustain angiogenesis, and evading apoptosis [1]. The whole paradigm was revised the following year to include metabolic reprogramming after a monumental effort had been spent on cancer metabolism studies [2]. Cancer metabolism was initially proposed by Otto Hendrich Warburg, termed Warburg’s effect, describing glucose consumption through glycolysis by cancer cells for ATP generation allowing tumor cell survival under aerobic condition [3]. In recent years, numerous studies have unraveled the dynamics of cancer metabolism and the concept of metabolic plasticity or metabolic rewiring of cancer cells was subsequently introduced. Apart from glucose utilization, cancer cells undergo various oncogenic mutations or adaptations to allow utilization of a more diverse range of nutrients including fatty acids (FAs) and amino acids for tumor survival, metastasis and disease progression. These findings have led to renewed interests to elucidate the diverse roles of lipid metabolism in cancer. This minireview aims to present current knowledge on fatty acid synthase FASN, its roles in cancer cell biology, metabolic reprogramming, and also the current challenges of FASN-targeted therapy. 2. FASN IN NORMAL PHYSIOLOGY FASN is a large multi-enzyme complex and the monomeric protein size is ~270 kDa. It comprises six separate enzymatic grooves that work together to produce a 16-carbon chain saturated fatty acid (FA), palmitate, from acetyl-coenzyme A (CoA) and malonyl-CoA in the presence of Nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) [4]. The FASN monomer (Figure 1) possesses enzymatic activities which include beta-ketoacyl synthase (KS), acetyl/malonyl transacylase (AT/MT), beta-hydroxyacyl dehydratase (DH), enoyl reductase (ER), beta-ketoacyl reductase (KR), acyl carrier protein (ACP), and thioesterase (TE). Although the FASN monomer contains all the necessary enzymes needed for palmitate synthesis, the dimer formation is crucial for its function. The structure of FASN can be further categorized into three major domains where domain I contains KS, AT/MT and DH, domain II contains ER, KR and ACP, and domain III contains TE. About a quarter length of the monomer protein, located between domains I and II, which lacks catalytic activity, is called the interdomain/core region and is identified to be crucial for dimer formation [5]. [Figure: Fatty acid synthase (FASN) structure. (A) Represents the linear sequence organization of FASN monomer. (B). Structural overview of FASN comprising two identical monomers, each including seven catalytic domains: beta-ketoacyl synthase (KS), acetyl/malonyl transacylase (AT/MT), beta-hydroxyacyl dehydratase (DH), enoyl reductase (ER), beta-ketoacyl reductase (KR), acyl carrier protein (ACP), and thioesterase (TE).] FASN expression is critical for early embryo development, in which FASN knockout (KO) embryos fail to survive before implantation and the number of FASN heterozygous pups is 70% lower than predicted by Mendelian Inheritance, which indicate partial haploid insufficiency [6]. Furthermore, FASN expression is shown to participate in the proper development of the fetal lung and the normal functionality of the adult lung. There is ample evidence demonstrating that the fetal lung is capable of de novo FA synthesis and that FASN is required for surfactant production of alveolar epithelial cells [7]. After early development, FASN remains relatively quiescent in most tissues, however the reason why this is so still remains elusive. A plausible explanation is that non-actively proliferating tissues can meet the FAs’ demand from the diet to fulfil their physiological FA requirements. Nonetheless, a strong FASN expression has been reported in the lung, breast, liver, adipose and brain [8]. Deletion of FASN in alveolar type II epithelial cells is found to disrupt surfactant lipid composition and exacerbate injury response to bleomycin-induced fibrosis [9]. The mature mammary gland is a unique lipid metabolizing tissue where, in resting-state, it does not require fatty acid synthesis but strongly induces FASN during pregnancy and lactation [10]. De novo FA synthesis in the mammary gland is responsible for producing short and medium chain FAs in milk, which account for ~15–40% of total FA content [11,12]. Mammary gland-specific FASN KO mice are shown to suffer from growth reduction in mammary epithelial cells, alteration of the FAs profile in milk from lactating mothers, and also improper development of the functional lactating mammary gland [13]. FASN is considered as a housekeeping protein in the liver under normal physiological conditions where it controls the hepatic triglyceride mechanism. When carbohydrates are abundant, glucose are converted to FAs with the help of FASN. Excess FAs are then assembled into triglycerides and stored in the form of lipid droplets or secreted as very low-density lipoproteins [14,15]. During fasting or under glucose-depleted conditions, lipid droplets undergo lipolysis or catabolism and fatty acid oxidation to produce ketone bodies which are then used as fuel [16]. In the brain, FASN is essential to maintain proper development and control lipid metabolism in neural stem cells. Neural stem cells are responsible, not only for early brain development, but also remain active for an entire life to ensure proper brain function. They divide and generate new nerve cells to enable the brain to adapt to new arrangements. Furthermore, disruption of lipid metabolism in neural stem cells, through the expression of a non-functional FASN, results in learning and memory deficits in humans and mice [17]. 3. FASN REGULATION FASN expression is regulated by external stimuli. A proposed mechanism for the upregulation of FASN transcription is through the activation of growth factor receptor (GFR) signaling pathways such as the epidermal growth factor receptor (EGFR), epidermal growth factor receptor 2 (HER2) and platelet-derived growth factor receptor (PDGFR) in tumor cells. The effects of GFR signaling on FASN regulation are complex and include cross-talk with other signal transduction pathways such as phosphatidylinositol-3′-kinase (PI3K) and extracellular regulated kinase 1/2 (ERK1/2). EGF activates EGFR activity, and together with ERK1/2 phosphorylation, they upregulate FASN in pancreatic ductal carcinoma (PDAC). Inhibition of EGFR by EGFR-specific siRNAs or EGFR-tyrosine kinase inhibitor (TKI) Erlotinib prevents FASN upregulation suggesting that EGFR activation is crucial for FASN upregulation [18]. Apart from EGFR, transcriptomic and protein analyses on HER2-amplified breast cancer cell lines showed enhanced FASN expression

Read the complete text